Vancouver, BC -- (SBWIRE) -- 05/07/2021 -- The global tumor genomics market is expected to reach a market size of 56.54 Billion by 2028 and register a double-digit CAGR over the forecast period, according to latest analysis by Emergen Research. The steady projected growth can be attributed to technological innovations in the field of genomics. Mergers and acquisitions between key players in the field is another key factor driving market growth. Increasing research on cancer, usage of genomic systems among academics and government institutions, and decreasing cost of sequencing is contributing significantly to growth in cancer diagnostics.

With an inspection of the financial standing of the leading companies operating in this market, the report provides information on their gross profits, revenue shares, sales volume, manufacturing costs, individual growth rate, and numerous other financial ratios. Our researchers have highlighted the market scope of the new entrants and established competitors using various analytical tools, including the SWOT analysis, investment assessment, and Porter's Five Forces Analysis.

Request a Sample Copy of the Report: https://www.emergenresearch.com/request-sample/531

Key Highlights of Report

In September 2018, Cancer Genetics Inc. and NovellusDx Ltd. signed a merger agreement in order to combine their data associated to tumor anatomy. The aim behind the merger is to enhance and accelerate the therapeutic development to improve treatment success rates for companies. With the proprietary technology and machine learning technology of NovellusDX Ltd., Cancer Genetics aims to form a leading oncology-focused precision medicine company.
Biomarkers play an important role in the detection of cancer and it may be used to detect early cancer symptoms or to perform differential diagnosis of cancerous tumors.
Revenue from the tumor genomic market in Asia Pacific is expected to expand at a rapid CAGR during the forecast period. This can be attributed to rising government funding for cancer detection and awareness, and introduction of state-of-the-art research institutions.
Key players in genomic biomarkers are Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Pacific Biosciences of California, Inc., NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., and PerkinElmer.

Market Segmentation:

Emergen Research has segmented the global tumor genomic market on the basis of technique, application, end-use, and region:

Technique Outlook (Revenue, USD Billion; 2021–2028)
Next Generation Sequencing Technique (NGS)
Polymerase Chain Reaction (PCR)
Microarray
In-Situ Hybridization (ISH)
Immunohistochemistry (ICH)
Others (Mass Spectrometry and Flow Cytometry)

Application Outlook (Revenue, USD Billion; 2021–2028)
Diagnostics and Monitoring
Drug Discovery and Development
Biomarker Discovery

End-use Outlook (Revenue, USD Billion; 2021–2028)
Academics and Research Organizations
Hospitals and Ambulatory Clinics
Clinical and Diagnostic Laboratories
Biotechnology and Pharmaceutical Company

Regional Landscape:

The report offers a comprehensive analysis of the current growth opportunities for various regions of the Tumor Genomic market, calculating their revenue share over the forecast timeline. Furthermore, the report analyzes the year-on-year growth rate of these regions over the forecast duration. The leading geographic regions encompassed in the report include:

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Request customization of the report @ https://www.emergenresearch.com/request-for-customization/531

Key questions addressed:

What are the estimated CAGR for the global Tumor Genomic market and each segment in the global market?
Which market segments and sub-segments have been covered in this report? Which of these segments is foreseen to exhibit the highest growth rate over the projected period? What are the most prominent industry aspects likely to impact the market values and shares of the regions viz., North America, Europe, Asia Pacific, Latin America, and Middle East &Asia? What do the SWOT analysis and Porter's five forces entailed in the report signify with respect to the future position of the market?
Which are the leading companies operating in the global Tumor Genomic market? What are their strengths and weaknesses?
What are the most common market expansion strategies applied by the key market competitors to reinforce their market positions?

Table of Content

Chapter 1. Methodology & Sources
    1.1. Market Definition
    1.2. Research Scope  
    1.3. Methodology
    1.4. Research Sources
          1.4.1. Primary
          1.4.2. Secondary
          1.4.3. Paid Sources
    1.5. Market Estimation Technique
Chapter 2. Executive Summary
    2.1. Summary Snapshot, 2020-2028
Chapter 3. Key Insights
Chapter 4. Tumor Genomics Market Segmentation & Impact Analysis
    4.1. Tumor Genomics Market Material Segmentation Analysis
    4.2. Industrial Outlook
          4.2.1. Market drivers analysis
                    4.2.1.1. Increasing number of cancer cases
                    4.2.1.2. Rising government initiatives and projects
                    4.2.1.3. Increasing demand for cancer specific diagnostics
                    4.2.1.4. Increasing use of biomarkers in cancer profiling
                    4.2.1.5. Introduction of cost-effective kits
                    4.2.1.6. Mergers and acquisitions between key players
          4.2.2. Market restraints analysis
                    4.2.2.1. High equipment cost
    4.3. Technological Insights 
    4.4. Regulatory Framework
    4.5. Porter's Five Forces Analysis
    4.6. Competitive Metric Space Analysis
    4.7. Price trend Analysis
    4.8. Covid-19 Impact Analysis

Chapter 5. Tumor Genomics Market By Technique Insights & Trends, Revenue (USD Billion)
    5.1. Technique and services Dynamics & Market Share, 2020 & 2028
          5.1.1. Next Generation Sequencing Technique (NGS)
          5.1.2. Polymerase Chain Reaction (PCR)
          5.1.3. Microarray
          5.1.4. In-Situ Hybridization (ISH)
          5.1.5. Immunohistochemistry (ICH)
          5.1.6. Others (Mass Spectrometry and Flow Cytometry) 

READ MORE…!

To know more about the report, visit: https://www.emergenresearch.com/industry-report/tumor-genomics-market

Thank you for reading our report. For more details on the report or to inquire about its customization, please let us know. We will offer you a report well-suited to your needs.

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Facebook | LinkdIn | Twitter | Blogs

Read Full Press Release: https://www.emergenresearch.com/press-release/global-tumor-genomic-market